Lung Cancer Clinical Trial
Official title:
Lung Cancer Screening in Family Members and Peers of Lung Cancer Patients: a Prospective Cohort Study
NCT number | NCT05645731 |
Other study ID # | MP-37-2023-9041 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 12, 2023 |
Est. completion date | April 2025 |
Lung cancer screening of active or former heavy smokers with yearly low-dose CT allows for earlier diagnosis and better lung cancer survival. Risk of developing lung cancer is higher among family members and close contacts of lung cancer patients, because of shared genetics, environment and life habits like smoking. The investigators want to engage lung cancer patients to refer their family members and close contacts for lung cancer screening, and evaluate if this referred population have higher risk of lung cancer than the population referred by their family doctors.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | April 2025 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Lung cancer patients: Inclusion Criteria: - > 18 years old - Current or former lung cancer patient Exclusion Criteria: none Referred participants Inclusion criteria: >18 years old Exclusion criteria: Personal history of lung cancer. |
Country | Name | City | State |
---|---|---|---|
Canada | MUHC | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Nicole Ezer, MD, FRCPC, MPH |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean number of referrals for lung cancer screening per participants | Mean number of referrals for lung cancer screening per participants: lung cancer participants will refer contacts directly on the REDCap questionnaire at enrollment. They will be contacted a second time 2 weeks after enrollment and asked if they referred additional people in their entourage for lung cancer screening. | 2 weeks post inclusion | |
Primary | Mean PLCOm2012 risk prediction model score among referred participants | Mean risk of developing lung cancer in the next 6 years using the validated PLCOm2012 risk prediction model in smokers or ex-smokers referred participants that are 55 to 74 years old. | baseline | |
Secondary | Number of visitors on our website for referred participants | Quantification of people who visited the website for close contacts of lung cancer patients: Number of unique access to website based on google analytics data. | 6 months | |
Secondary | Number of people who started to fill the enrollment form for referred participants. | Number of people who started to fill the enrollment form for referred participants. | 6 months | |
Secondary | Number of referred participants who enrolled in the study. | Number of referred participants who enrolled in the study. | 6 months | |
Secondary | PLCO score as a binary outcome (above or below 2%) among referred participants | baseline | ||
Secondary | Proportion of LCS eligible participants who will complete lung cancer screening within 18 months of referral by a lung cancer patient | Proportion of LCS eligible participants who will complete lung cancer screening within 18 months of referral by a lung cancer patient | 18 months | |
Secondary | Proportion of individuals who would theoretically demonstrate interest in genetic testing to assess for lung cancer risk. | Proportion of individuals who would theoretically demonstrate interest in genetic testing to assess for lung cancer risk. | baseline | |
Secondary | Proportion of individuals who demonstrate interest in referral to a smoking cessation program among referred participants that are current smokers | Proportion of individuals who demonstrate interest in referral to a smoking cessation program among referred participants that are current smokers | baseline | |
Secondary | Anxiety regarding lung cancer for referred participants | GAD7 | baseline | |
Secondary | Anxiety regarding lung cancer for referred participants | GAD7 | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|